446 related articles for article (PubMed ID: 28666686)
1. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
[TBL] [Abstract][Full Text] [Related]
2. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
3. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
[TBL] [Abstract][Full Text] [Related]
4. Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma.
Huebner M; Kendrick M; Reid-Lombardo KM; Que F; Therneau T; Qin R; Donohue J; Nagorney D; Farnell M; Sarr M
J Gastrointest Surg; 2012 May; 16(5):920-6. PubMed ID: 22421988
[TBL] [Abstract][Full Text] [Related]
5. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
6. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
7. Lymph node size and metastatic infiltration in adenocarcinoma of the pancreatic head.
Prenzel KL; Hölscher AH; Vallböhmer D; Drebber U; Gutschow CA; Mönig SP; Stippel DL
Eur J Surg Oncol; 2010 Oct; 36(10):993-6. PubMed ID: 20594789
[TBL] [Abstract][Full Text] [Related]
8. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma.
Ashfaq A; Pockaj BA; Gray RJ; Halfdanarson TR; Wasif N
J Gastrointest Surg; 2014 Nov; 18(11):1929-35. PubMed ID: 24916590
[TBL] [Abstract][Full Text] [Related]
9. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
10. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.
Riediger H; Keck T; Wellner U; zur Hausen A; Adam U; Hopt UT; Makowiec F
J Gastrointest Surg; 2009 Jul; 13(7):1337-44. PubMed ID: 19418101
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
[TBL] [Abstract][Full Text] [Related]
12. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma.
Sada YH; Smaglo BG; Tan JC; Tran Cao HS; Musher BL; Massarweh NN
J Natl Compr Canc Netw; 2019 Feb; 17(2):161-168. PubMed ID: 30787129
[No Abstract] [Full Text] [Related]
14. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
15. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
[TBL] [Abstract][Full Text] [Related]
16. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer.
Honselmann KC; Pergolini I; Castillo CF; Deshpande V; Ting D; Taylor MS; Bolm L; Qadan M; Wellner U; Sandini M; Bausch D; Warshaw AL; Lillemoe KD; Keck T; Ferrone CR
Ann Surg; 2020 Aug; 272(2):357-365. PubMed ID: 32675550
[TBL] [Abstract][Full Text] [Related]
17. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
Hackert T; Ulrich A; Büchler MW
Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331
[No Abstract] [Full Text] [Related]
18. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing.
Oppliger FA; Prakash LR; Newhook TE; Chiang YJ; Ikoma N; Maxwell JE; Kim MP; Vauthey JN; Lee JE; Katz MH; Tzeng CD
Surg Oncol; 2022 Mar; 40():101673. PubMed ID: 34894620
[TBL] [Abstract][Full Text] [Related]
19. Evolution and impact of lymph node dissection during pancreaticoduodenectomy for pancreatic cancer.
Eskander MF; de Geus SW; Kasumova GG; Ng SC; Al-Refaie W; Ayata G; Tseng JF
Surgery; 2017 Apr; 161(4):968-976. PubMed ID: 27865602
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
